Jump Financial LLC lessened its stake in shares of Immunocore Holdings plc (NASDAQ:IMCR - Free Report) by 46.2% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 32,600 shares of the company's stock after selling 28,022 shares during the quarter. Jump Financial LLC owned about 0.07% of Immunocore worth $962,000 at the end of the most recent reporting period.
Other institutional investors have also recently added to or reduced their stakes in the company. State Street Corp lifted its holdings in Immunocore by 63.9% in the 3rd quarter. State Street Corp now owns 76,671 shares of the company's stock worth $2,387,000 after buying an additional 29,897 shares in the last quarter. Principal Financial Group Inc. grew its position in shares of Immunocore by 25.0% in the 3rd quarter. Principal Financial Group Inc. now owns 546,318 shares of the company's stock worth $17,007,000 after acquiring an additional 109,206 shares in the last quarter. Hennion & Walsh Asset Management Inc. raised its position in shares of Immunocore by 125.4% during the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 49,608 shares of the company's stock valued at $1,463,000 after acquiring an additional 27,598 shares in the last quarter. Crossmark Global Holdings Inc. boosted its holdings in Immunocore by 36.7% in the fourth quarter. Crossmark Global Holdings Inc. now owns 38,020 shares of the company's stock worth $1,121,000 after purchasing an additional 10,217 shares during the period. Finally, Legal & General Group Plc lifted its position in shares of Immunocore by 17.3% in the 4th quarter. Legal & General Group Plc now owns 136,875 shares of the company's stock worth $4,038,000 after buying an additional 20,163 shares during the last quarter. Institutional investors and hedge funds own 84.50% of the company's stock.
Immunocore Stock Down 0.7 %
NASDAQ IMCR traded down $0.20 on Friday, reaching $30.16. The stock had a trading volume of 251,246 shares, compared to its average volume of 437,957. The business has a 50 day moving average price of $28.77 and a 200 day moving average price of $30.35. Immunocore Holdings plc has a 1 year low of $23.15 and a 1 year high of $62.74. The company has a market capitalization of $1.51 billion, a price-to-earnings ratio of -31.75 and a beta of 0.75. The company has a current ratio of 3.78, a quick ratio of 3.76 and a debt-to-equity ratio of 1.03.
Wall Street Analyst Weigh In
A number of equities analysts have issued reports on IMCR shares. Mizuho cut their target price on shares of Immunocore from $38.00 to $33.00 and set a "neutral" rating on the stock in a report on Monday, April 7th. Morgan Stanley reaffirmed an "equal weight" rating and issued a $35.00 target price on shares of Immunocore in a research report on Friday, March 7th. Needham & Company LLC reissued a "buy" rating and set a $71.00 price target on shares of Immunocore in a report on Thursday, April 10th. JPMorgan Chase & Co. lowered their target price on Immunocore from $54.00 to $50.00 and set an "overweight" rating on the stock in a research report on Monday, April 14th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $100.00 price target on shares of Immunocore in a research note on Wednesday, March 12th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $60.90.
Get Our Latest Report on Immunocore
Insider Buying and Selling at Immunocore
In related news, Director Bros. Advisors Lp Baker bought 807,338 shares of the business's stock in a transaction on Monday, March 17th. The shares were bought at an average cost of $29.72 per share, for a total transaction of $23,994,085.36. Following the completion of the acquisition, the director now directly owns 2,144,060 shares in the company, valued at approximately $63,721,463.20. This represents a 60.40 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 10.40% of the company's stock.
Immunocore Company Profile
(
Free Report)
Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.
See Also
Before you consider Immunocore, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immunocore wasn't on the list.
While Immunocore currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
